Medico Remedies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 08, 2025.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Remedies Limited's board, which met on May 8, 2025, approved audited standalone financial results for Q4 and full year ended March 31, 2025. Full-year revenue from operations rose modestly to Rs. 15,094 lakhs (from Rs. 14,492 lakhs in FY24), while profit after tax grew about 22% to Rs. 1,009 lakhs (from Rs. 829 lakhs), pushing EPS to Rs. 1.22 (from Rs. 1.00). Statutory auditors VJ Shah & Co issued an unmodified opinion and will retire on completion of their term at the 31st AGM. The board appointed Shah Shroff & Associates as the new statutory auditor for a five-year term and Mr. Haresh Sanghvi as secretarial auditor for FY2025-26 to FY2029-30, both subject to shareholder approval. The board also approved the Board's Report, Management Discussion & Analysis, and Corporate Governance Report for FY25.
Strong earnings growth (PAT up ~22% YoY) is a positive signal for shareholders, though rising trade receivables and inventory, along with higher short-term borrowings, are points to watch. The routine change of statutory auditors is procedural and not expected to materially affect operations.